Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc., a clinical-stage company specializing in heart disease treatments, has announced a public offering of Class A common shares to fund the development of CardiolRx and other company expenses. The final details of the offering will be determined based on market context, with no assurance of completion or the terms of the offering.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
